Immuron Limited - Warrants (12/05/2022) Return on Equity

Immuron Limited - Warrants (12/05/2022) posts a ROE of -60.24%. That is above the Healthcare sector average of -75.84%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near -75.84% is typical. Immuron Limited - Warrants (12/05/2022)'s -60.24% is higher that level. That is roughly 20.6% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Immuron Limited - Warrants (12/05/2022)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -60.24%; use YoY and peer views to separate noise from signal.

Context for IMRNW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -75.84%), and (3) consistency with growth and profitability. This page covers the first two; Immuron Limited - Warrants (12/05/2022)'s other metric pages and overview cover the third.

Judging Immuron Limited - Warrants (12/05/2022) against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -60.24% here, then scan peer and history charts to see if the gap is persistent.